TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04454723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood and/or platelet transfusion
Description: The transfused patients will receive one unit each of blood and/or platelet transfusions once a week based on CTCAE symptom grade 2 or greater of anemia and/or thrombocytopenia.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete blood count (CBC) collection
Description: CBC will be collected from patients weekly while on this protocol.
Study: NCT00722865

Intervention type: DRUG
Group type: OTHER
Intervention: Avastin
Description: Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
Study: NCT02825550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Taiwan ACE Beads
Description: Similar with conventional TACE, radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
Study: NCT01365546

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human VWF/FVIII concentrate
Description: intravenous infusion. Dose based on subject's individual invivo-recovery
Study: NCT03461081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine and atorvastatin
Description: Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan/amlodipine and atorvastatin
Description: Telmisartan/Amlodipine(40/5 mg) 2 Tab for 10 days Telmisartan/Amlodipine(40/5 mg) 2 Tab with Atorvastatin 40 mg 1 Tab for 4 days Atorvastatin 40 mg 1 Tab for 4 days
Study: NCT02566733

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remiva
Description: Target controlled infusion of remifentanil (generic drug, Remiva™)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ultiva
Description: Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
Study: NCT00760838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin 250 mg
Description: Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Study: NCT03518450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apex Femoral Triangle Block
Description: Nerve block that aims the vastus medialis nerve, the saphenous nerve and the anterior femoral cutaneous nerve.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Regional anesthetic technique that blocks the sensory and motor information of the femoral nerve (and it's branches).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Adductor Canal Block
Description: Interfascial block that targets mainly the saphenous nerve.
Study: NCT03846817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led treatment
Description: 12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led treatment
Description: 12-week of semi-standardized, progressive physiotherapist-led treatment aiming to increase hip muscle strength and load capacity.
Study: NCT03366571

Intervention type: DRUG
Intervention: Nucleos(t)ide Analogues
Description: Entecavir 0.5mg daily, Lamivudine100mg qd daily, Adefovir Dipivoxil 10mg daily, telbivudine 600mg qd daily, their combination therapy, tenofovir 300mg qd daily.
Study: NCT04243954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA IV Hydromorphone (continuous dose = 0)
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose = 0; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours: 3) lockout time = 10 minutes; 4) evaluate once every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA IV Hydromorphone (continuous dose ≠ 0)
Description: Intravenous PCA with hydromorphone after successful titration of 24 hours. the PCA setting: 1) continuous dose (dose/hours) = the total dosage of hydromorphone in the previous 24 hours/24; 2) bolus dose = 10-20% of the total dosage of hydromorphone in the previous 24 hours; 3) lockout time = 10 minutes; 4) evaluate once every 24 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral morphine
Description: Swift to sustained-release morphine orally as background dose with immediate release morphine orally for breakthrough pain after successful titration of 24 hours.~Administration of morphine orally 1) Sustained-release morphine orally (dose/12 hours) = the total equianalgesic of the previous 24 hours/2×75% for d1; the total equianalgesic of the previous 24 hours/2 for day 2 and day 3; 2) Immediate release morphine orally = 10-20% of the total equianalgesic of the previous 24 hours; 3) Evaluate once every 24 hours
Study: NCT03741621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viscous Fibre Blend
Description: High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Psyllium
Description: Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat Bran
Description: All Bran cereal (All Bran®; Kellogg Company)
Study: NCT02991118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bempedoic acid
Description: bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
Study: NCT00760838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
Study: NCT00447122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m2 30 minutes
Description: 1000mg/m2 30 minutes
Study: NCT00110032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EF5
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 EF5
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 EF5
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT00069706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-12182 0.003% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: AL-12182 Ophthalmic Solution Vehicle
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% Ophthalmic Solution
Description: Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-12182 0.01% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-12182 0.03% Ophthalmic Solution
Description: Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
Study: NCT01264874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 ( Colecalciferol)
Description: 100000 IU every 50 days for 3 years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For 3 years IU every 50 days
Study: NCT02845609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sialic Acid-Extended Release
Description: Oral drug of Sialic acid
Study: NCT02180932

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: periodontal pocket samples
Study: NCT03021616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy drink
Description: 32oz of commercially available energy drink

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400mg
Description: 400mg moxifloxacin active control drink

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo drink
Study: NCT02602691

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AlloMap®
Study: NCT00447122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m2 30 minutes
Description: 1000mg/m2 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib 1000mg/d
Description: 1000mg/d
Study: NCT02602691

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endomyocardial biopsies
Study: NCT00551421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pertuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT02536209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00447122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib 1000mg/d
Description: 1000mg/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500mg/d
Description: 1500mg/d
Study: NCT02536209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00551421

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: polymerase chain reaction
Description: Correlative study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative study
Study: NCT00447122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib 1500mg/d
Description: 1500mg/d
Study: NCT01838603

Intervention type: OTHER
Intervention: Qualitative interview
Description: Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
Study: NCT03788226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POF
Description: A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAPOX/SOX/FOLFOX
Description: CAPOX: IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days for 8 cycles.~SOX: Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO \[BSA \<1.25 40mg bid (total 80mg/day); BSA ≥1.25 - \<1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)\], divided by two on D1-14 every 21 days for 8 cycles.~mFOLFOX6: IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days for 12 cycles.
Study: NCT00836537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril HCl 40 mg Tablets
Description: 1 x 40 mg, single-dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lotensin® 40 mg Tablets
Description: 1 x 40 mg, single-dose fed
Study: NCT01910194

Intervention type: DRUG
Group type: OTHER
Intervention: Luyxumia versus Lantus

Intervention type: DRUG
Group type: OTHER
Intervention: Luyxumia versus Lantus
Study: NCT00734682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanoliposomal CPT-11
Description: Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m\^2 (wild type) or 60 mg/m\^2 IV q3 weeks.
Study: NCT03064906

Intervention type: DEVICE
Group type: OTHER
Intervention: Insulet AP (artificial pancreas) System
Description: Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
Study: NCT02170207

Intervention type: DRUG
Intervention: Lansoprazole
Description: Lansoprazole 30 mg injection
Study: NCT04263688

Intervention type: OTHER
Intervention: Non-Intervention
Description: Non-Intervention
Study: NCT00447122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m2 100minutes
Description: 1000mg/m2 100minutes
Study: NCT02627794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restora™ Steroid eluting spacer
Description: The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
Study: NCT00447122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000mg/m2 100minutes
Description: 1000mg/m2 100minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 100mg/m2
Description: 100mg/m2
Study: NCT02627794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silastic Silicone Spacer
Description: The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
Study: NCT05647538

Intervention type: PROCEDURE
Intervention: Bilateral uterine artery ligation
Description: Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.

Intervention type: PROCEDURE
Intervention: Bilateral uterine artery ligation
Description: Bilateral UAL was done 2 cm under the Kerr incision (lower segment transverse). A 2-Vicryl absorbable suture (Ethicon, Neuilly-surSeine, France) was introduced from the anterior to posterior views of the myometrium 2-3 cm medial to the descending part of the uterine vessels within an avascular area in the broad ligament and tied. Following the surgery, the uterine tone and hemorrhage were managed.
Study: NCT00447122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 100mg/m2
Description: 100mg/m2
Study: NCT00915551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP005 (Ingenol Mebutate) gel, 0.015%
Description: once daily for 3 consecutive days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: once daily for 3 consecutive days
Study: NCT02039856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multilevel stakeholder engagement
Description: Structured, in-person stakeholder panel meeting of VA network, VA medical center, and primary care and women's health leaders using modified Delphi panel techniques to come to consensus on a quality improvement (QI) roadmap within each participating VA network, followed by intermittent progress reporting and post-24 months in-person capstone stakeholder panel meetings

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality improvement (QI) education/training
Description: Initial in-person and ongoing virtual team training in QI principles, methods, and project proposal development and refinement
Study: NCT03137849

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Poses
Description: Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
Study: NCT02540460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 1200mg BID
Description: LCB01-0371 1200mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02109614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release Niacin
Description: Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo Comparator arm will be taking 1500mg of the placebo daily
Study: NCT03854656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Participants will be instructed to eat within a self-selected 10-hour timeframe between 6AM and 8PM every day. All food/beverages except water must be consumed within the time-interval. Staff will help participants select a time-interval that fits into their daily life and optimally fulfil the following guiding principles:~1. The first food item/beverage of the day should optimally be ingested at least 2 hours after usual wake-up time~2. The last food item/beverage of the day should optimally be ingested at least 3 hours before usual bed time~Diet is ad libitum and with no further dietary restrictions. Participants will receive advice about a healthy lifestyle according to the national dietary recommendations from the Danish Health Authority.
Study: NCT03836547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching and Weight Loss for patients with dyspnea
Description: Patients with lung disease and a BMI of 35 or greater who suffer from shortness of breath will be invited to participate in a study involving a commercial weight loss application with health coaching. The patients will subscribe on their own to the weight loss application. The patients will be provided with a blue tooth scale so that they may weigh themselves weekly. A health coach will call them weekly for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants will receive usual care for 12 weeks followed by the active intervention.
Study: NCT03025542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Based on their randomization subjects will receive a combination of several injections of Bimekizumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimekizumab
Description: Based on their randomization subjects will receive a combination of several injections of Bimekizumab.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive injections of Placebo.
Study: NCT02039856

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Technical support
Description: Research team provided technical review of and feedback on local QI project proposals, helped develop and/or recommend process/outcome measures, identified and shared relevant published literature (e.g., measures, interventions), and provided general technical support (e.g., how to analyze local data, how to conduct a local focus group)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formative feedback
Description: Research team provided aggregated all-site and local data from baseline patient and provider/staff surveys, 12-month patient surveys, and other data and findings to local teams for ongoing and new QI project idea development

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External practice facilitation
Description: Within and across site calls with local teams to review progress, identify needs, help solve problems, discuss current and new projects, as well as potential for spread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: National policy guidance
Description: VA Handbooks on policy and practice for PACT implementation guidance and on delivery of comprehensive women's health services disseminated to all VA facilities
Study: NCT01384396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-3357
Description: Intravenous infusion once a day
Study: NCT00616460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT \< 250
Study: NCT03609515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-controlled admission
Description: The patients with a contract for patient-controlled admissions may refer themselves to short inpatient stays when they feel the need, without needing an approval from a clinician. They will be accepted for admission if a patient-controlled bed is available in the ward. Patient-controlled admissions are limited to a length of 5 days and at least three weeks between such stays.